Review article · 2025 · Open access

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon

Dehong Wu, Zijun Yidan Xu-Monette, Jia Zhou, Kepeng Yang, Xinchang Wang, Yongsheng Fan, Ken H. Young

Frontiers in Immunology, 16, 1613878 · Published 12 August 2025 · DOI 10.3389/fimmu.2025.1613878

Open PDFView at the publisherCite this paper

In brief

“CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon” is a 2025 review article by Dehong Wu and 6 co-authors, published in Frontiers in Immunology. OpenAlex counts 50 citations as of 19 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
50
Most cited in
2026 (42)
Field-weighted impact
4.09
References
213
Authors
7

Abstract

Although current treatments for autoimmune diseases can effectively control symptoms, they rarely lead to cures and often require lifelong use, accompanied by considerable adverse effects. This emphasizes the urgent need for more targeted therapies that offer long-term efficacy and curative potential. Chimeric antigen receptor (CAR) T-cell therapy presents a promising option by specifically targeting and eliminating autoreactive B cells, with the potential to reset the patient's immune system and promote long-term immune balance. Originally developed for treating hematologic malignancies, where it has achieved remarkable success, recent studies have demonstrated substantial promise of CAR T-cell therapy, such as systemic lupus erythematosus (SLE) and myasthenia gravis. This article provides an overview of the current progress in CAR T-cell therapy for autoimmune diseases, focusing on five key approaches: CD19-targeted CAR T cells, CAR T cells targeting long-lived plasma cells, CAR T cells targeting specific autoantibodies, organ-specific CAR regulatory T cells (Treg cells), and mRNA-engineered CAR T cells. Additionally, this article discusses strategies for optimizing CAR T-cell therapy, including "off-the-shelf" allogeneic CAR T-cell therapy, combined CAR T-cell therapy, establishing timely consensus guidelines for their application in autoimmune diseases, and risk stratification strategies aimed at enhancing the personalization of treatments and minimizing adverse effects. While current research results are promising, further large-scale clinical trials and long-term follow-up are essential to thoroughly evaluate the safety and efficacy of CAR T-cell therapy in autoimmune diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wu, D., Xu-Monette, Z. Y., Zhou, J., Yang, K., Wang, X., Fan, Y., & Young, K. H. (2025). CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Frontiers in Immunology, 16, 1613878. https://doi.org/10.3389/fimmu.2025.1613878

MLA 9

Wu, Dehong, et al. “CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.” Frontiers in Immunology, vol. 16, 2025, p. 1613878. https://doi.org/10.3389/fimmu.2025.1613878.

Chicago

Wu, Dehong, Zijun Yidan Xu-Monette, Jia Zhou, Kepeng Yang, Xinchang Wang, Yongsheng Fan, and Ken H. Young. 2025. “CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.” Frontiers in Immunology 16: 1613878. https://doi.org/10.3389/fimmu.2025.1613878.

Harvard

Wu, D. et al. (2025) ‘CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon’, Frontiers in Immunology, 16, p. 1613878. doi:10.3389/fimmu.2025.1613878.

IEEE

D. Wu et al., “CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon,” Frontiers in Immunology, vol. 16, p. 1613878, 2025, doi: 10.3389/fimmu.2025.1613878.

BibTeX

@article{wu2025cell,
  title     = {{CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon}},
  author    = {Wu, Dehong and Xu-Monette, Zijun Yidan and Zhou, Jia and Yang, Kepeng and Wang, Xinchang and Fan, Yongsheng and Young, Ken H.},
  journal   = {Frontiers in Immunology},
  year      = {2025},
  volume    = {16},
  pages     = {1613878},
  doi       = {10.3389/fimmu.2025.1613878},
  url       = {https://doi.org/10.3389/fimmu.2025.1613878}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • CAR T-cell therapy
  • autoimmune disease
  • systemic lupus erythematosus
  • myasthenia gravis
  • CD19 CAR T cells
  • long-lived plasma cells
  • regulatory T cells
  • allogeneic CAR T cells

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wu, D., Xu-Monette, Z. Y., Zhou, J., Yang, K., Wang, X., Fan, Y., & Young, K. H. (2025). CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Frontiers in Immunology, 16, 1613878. https://doi.org/10.3389/fimmu.2025.1613878

How many times has this paper been cited?

50 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Dehong Wu, Zijun Yidan Xu-Monette, Jia Zhou, Kepeng Yang, Xinchang Wang, Yongsheng Fan, Ken H. Young.

What is the DOI of this paper?

10.3389/fimmu.2025.1613878, permanently at https://doi.org/10.3389/fimmu.2025.1613878. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.